UNH · Q2 2026 Earnings

Bullish

UnitedHealth Group

Reported July 16, 2026

30-second summary

Revenue was essentially flat at $112.0B (+0.4% YoY, +0.3% QoQ) with adjusted EPS of $6.38 crushing the $4.85 consensus by 31.6% and MCR landing at 86.7%. Management raised FY2026 adjusted EPS guidance ~8% at midpoint to $19.50–$20.00 (from >$18.25), lifted the buyback commitment 150% to at least $5.0B, and — most importantly — restored the full operational framework (MCR 88.1% ±25bps, operating earnings >$25.45B, OCF ~$24B, tax rate ~18.5%) that was withdrawn just one quarter ago. The ±25bps MCR band is tighter than the ±50bps issued in Q4 FY2025, suggesting management now has enough cost visibility to commit publicly again.

Headline numbers

EPS

Q2 FY2026

$6.38

Revenue

Q2 FY2026

$112.03B

+0.4% YoY

+1.1% vs est.

Operating margin

Q2 FY2026

7.1%

Key financials

Q2 FY2026

Metric	Q2 FY2026	Q2 FY2025	YoY	Q1 FY2026	QoQ
Revenue	$112.03B	$111.60B	+0.4%	$111.70B	+0.3%
EPS	$6.38	$4.08	+56.4%	$7.23	-11.8%
Operating margin	7.1%	4.6%	+250bps	8.0%	-90bps

Guidance

UnitedHealth raised full-year 2026 adjusted EPS guidance to $19.50–$20.00 (from >$18.25), a ~8% raise at midpoint, and elevated full-year share repurchase commitment to at least $5.0B (from $2.0B by end of Q2), signaling strong operational momentum and confidence in capital allocation.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

Metric	Period	Guide	YoY
Operating Earnings	FY 2026	> $25,450 million	—
Medical Care Ratio	FY 2026	88.1% ± 25 bps	—
Cash Flows from Operations	FY 2026	~$24,000 million	—
Tax Rate	FY 2026	~18.5%	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Diluted Net Earnings per Share (non-GAAP)	FY 2026	> $18.25	$19.50 to $20.00	+$1.25 to +$1.75 at midpoint (+6.8% to +9.6%)	Raised
Diluted Net Earnings per Share (GAAP)	FY 2026	> $17.35	$18.45 to $18.95	+$1.10 to +$1.60 at midpoint (+6.3% to +9.2%)	Raised
Share Repurchase	FY 2026	At Least $2,000 million (by end of Q2)	At Least $5,000 million	+ $3,000 million (150% increase to full-year buyback target)	Raised

Reaffirmed unchanged this quarter: Debt-to-Capital Ratio (approximately 40.0% (back half of 2026))

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
UnitedHealthcare	$86.017B	$86.1B	-0.1%
Optum	$65.663B	$67.2B	-2.3%
Optum Health	$23.472B	$25.2B	-6.9%
Optum Insight	$5.402B	$4.8B	+12.5%
Optum Rx	$38.292B	$38.5B	-0.5%
UnitedHealthcare Employer & Individual	$19.992B	—	+1.1%
UnitedHealthcare Medicare & Retirement	$42.39B	—	-0.5%
UnitedHealthcare Community & State	$23.635B	—	-0.3%

Other KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Medical Care Ratio (MCR)	86.7%	—	—
Operating Cost Ratio	12.7%	12.3%	—
UnitedHealthcare Operating Margin	4.6%	—	—
Optum Operating Margin	6.2%	—	—
UnitedHealthcare Consumers Served	48.5 million	—	—
Optum Consumers Served	120+ million	—	—
Optum Rx Adjusted Scripts	387 million	414 million	—
Debt-to-Capital Ratio	41.2%	—	—

Management tone

Q1 FY2025 operational excellence → Q2 FY2025 "we've made mistakes" → Q3 FY2025 frameworks withdrawn → Q4 FY2025 frameworks restored (±50bps) → Q1 FY2026 frameworks withdrawn again → Q2 FY2026 frameworks fully restored with tighter ±25bps MCR band

The disclosure posture has now cycled four times in six quarters, but this quarter's restoration is meaningfully firmer than Q4 FY2025's. Two quarters ago management re-issued MCR at ±50bps; last quarter it was withdrawn again; this quarter it's back at ±25bps — tighter than any point since Q1 FY2025. The press release language — "raised guidance for full year 2026," "improved outlook for the remainder of the year," "continuing progress in our work to simplify how we operate" — is the most unambiguously forward-leaning tone UNH has used since new-CEO Hemsley took over. That management is willing to commit to a 25bp MCR band after a Q2 print of 86.7% (well below the 88.1% midpoint) signals internal confidence that H2 seasonal deterioration is bounded.

The second shift is in capital return posture. Three quarters ago (Q4 FY2025) the FY OCF was guided down to $18B from $19.7B; two quarters ago (Q1 FY2026) that OCF guide was withdrawn while a modest ≥$2B buyback commitment was disclosed as substitute; this quarter OCF is restored at ~$24B (+$6B above the withdrawn floor) and the buyback commitment is lifted 150% to ≥$5B. The substitution logic from Q1 has been reversed — operational accountability is back AND capital return has been elevated. That combination is a much stronger signal than either move in isolation.

The third shift, more speculative absent transcript, is in Optum Health framing. Revenue there decelerated further to -5.1% YoY, but management's press-release language about "simplifying how we operate" positions this as engineered contraction rather than involuntary loss. The +52% YoY operating earnings recovery on the recast $1.45B base remains implicit in the >$25.45B operating earnings floor. Whether the leaner book is generating enough incremental profitability per patient to deliver against that target is the H2 test.

Answers to last quarter's watch list

Whether the operating margin, MCR, OCR, and OCF guidance frameworks are re-issued at the Q2 FY2026 print or remain withdrawn. Fully restored, and with a tighter MCR band than Q4 FY2025 (±25bps vs ±50bps). MCR guided to 88.1% ±25bps, operating earnings >$25.45B (implying operating margin), OCF ~$24B. This is the most complete framework since Q1 FY2025 and reverses the Q1 FY2026 withdrawal decisively.

Resolved positively

Q2 FY2026 OCR specifically — does it move below 13.8% or stay elevated? Q2 OCR came in at 12.7%, 110bps below Q1's 13.8% and inside the ±50bps band around the prior 12.8% midpoint that had been withdrawn. The cost framework was not pulled because it was failing — Q2 confirms the Q1 elevation was transient.

Resolved positively

Optum Health Q2 FY2026 revenue — does the -3% Q1 decline narrow toward zero or widen further? Widened materially, from -3% in Q1 to -5.1% in Q2. Fourth consecutive quarter of contraction. This strains the +52% YoY operating earnings recovery on the recast $1.45B FY2025 base — the leaner book must generate substantially more profit per patient than the prior larger book to hit the >$2.2B implicit FY2026 Optum Health target.

Resolved negatively

Sizing of the acuity component disclosed in Q2. The company didn't quantify the acuity/provider-billing component in the press release. Without transcript commentary, this remains open.

Continue monitoring

CMS GLP-1 bridge demo signal post-July start. Not addressed in the press release.

Continue monitoring

What to watch into next quarter

Q3 FY2026 MCR vs the 88.1% ±25bps band. Q2 FY2026 came in at 86.7%, 140bps below midpoint. The seasonal pattern requires H2 MCR to run notably above midpoint — a Q3 print above 88.35% (top of band) would signal H2 deterioration is running hotter than the seasonal frame implies, testing the newly restored ±25bps commitment.

Optum Health revenue trajectory — does the -5.1% decline stabilize or continue widening? The trend from -0.5% (Q4 FY2025) → -3% (Q1 FY2026) → -5.1% (Q2 FY2026) has accelerated for three consecutive quarters. A Q3 revenue decline steeper than -5% forces a reassessment of the implicit FY2026 >$2.2B Optum Health operating earnings target, given H1 was supposed to carry most of the earnings weight.

Operating cash flow vs the ~$24B FY guide. Nine-month OCF cumulative vs the ~$24B implicit run-rate will reveal whether the $6B step-up from the withdrawn $18B Q1 guide is genuine cash conversion improvement or partial timing reversal from FY2025.

Whether the buyback pace matches the ≥$5B commitment. Q2 press release confirms lifted target; watch cumulative repurchases disclosed in Q3 to confirm capital return acceleration is real rather than aspirational.

Initial FY2027 framework signal. With FY2026 adjusted EPS now guided to a $19.50–$20.00 range, the 2027 return to the upper half of the 2–4% MA margin range (per Q1 FY2026 commentary) becomes the next quantifiable inflection. Q3 FY2026 is when management historically begins to shape the following-year set-up.

Sources

UnitedHealth Group Q2 FY2026 Press Release / Form 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/731766/000073176626000191/earningsrelease2q26_7152.htm
Tapebrief UNH Q1 FY2026, Q4 FY2025, Q3 FY2025, and Q2 FY2025 briefs (prior coverage)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.